Market Summary
USD87.50-1.58
Delayed-1.77%
DXCM Stock Price
DXCM RSI Chart
DXCM Valuation
DXCM Price/Sales (Trailing)
DXCM Profitability
DXCM Fundamentals
DXCM Revenue
DXCM Earnings
Price Action
52 Week Range
78.94139.55
(Low)(High)
Last 7 days
-9.2%
Last 30 days
-16.2%
Last 90 days
-31.0%
Trailing 12 Months
8.1%
DXCM Financial Health
DXCM Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for DXCM
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | ALTMAN STEVEN R | sold | -101,495 | 101 | -1,000 | - |
2023-09-12 | Heller Bridgette P | sold | -63,936 | 106 | -600 | - |
2023-09-11 | Selvaraj Shelly Ramasamy | back to issuer | -215,241 | 105 | -2,045 | svp chief information officer |
2023-09-01 | Dolan Matthew Vincent | sold | -5,729 | 102 | -56.00 | svp corporate strategy-develop |
2023-08-24 | Driscoll Rimma | acquired | - | - | 4,008 | - |
2023-08-23 | Pacelli Steven Robert | sold | -43,989 | 107 | -411 | evp managing director dexcom v |
2023-08-22 | Sylvain Jereme M | sold | -192,477 | 104 | -1,844 | evp chief financial officer |
2023-08-11 | Dahut Karen M | gifted | - | - | -1,544 | - |
2023-08-11 | Dahut Karen M | gifted | - | - | 1,544 | - |
2023-08-09 | Stern Sadie | sold | -43,398 | 110 | -392 | evp chief human resources offi |
Which funds bought or sold DXCM recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | new | - | 766,419 | 766,419 | 0.01% |
2023-09-20 | BARCLAYS PLC | added | 89.26 | 53,350,000 | 102,139,000 | 0.06% |
2023-09-12 | Farther Finance Advisors, LLC | added | 1.18 | 4,706 | 44,207 | 0.01% |
2023-09-12 | Prosperity Financial Group, Inc. | added | 6.62 | 45,637 | 300,071 | 0.26% |
2023-09-11 | BLUEFIN CAPITAL MANAGEMENT, LLC | new | - | 31,818,100 | 31,818,100 | 6.08% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 1,028 | 1,028 | -% |
2023-09-07 | JAG CAPITAL MANAGEMENT, LLC | reduced | -1.04 | 878,516 | 10,161,400 | 1.17% |
2023-09-05 | Covenant Partners, LLC | added | 2.58 | 65,443 | 551,308 | 0.20% |
2023-08-29 | EFG Asset Management (Americas) Corp. | reduced | -10.21 | -3,062 | 447,600 | 0.10% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | 227 | 7,808 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of DexCom
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 10, 2023 | blackrock inc. | 8.7% | 33,535,680 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 11.34% | 43,819,836 | SC 13G/A | |
| Jan 27, 2023 | blackrock inc. | 8.7% | 33,882,680 | SC 13G/A | |
| Jan 25, 2023 | blackrock inc. | 8.8% | 33,882,680 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 10.74% | 10,410,319 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 08, 2022 | blackrock inc. | 8.4% | 8,128,454 | SC 13G/A | |
| Dec 06, 2021 | baillie gifford & co | 4.85% | 4,700,380 | SC 13G/A | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 2.2% | 2,139,304 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.66% | 10,232,245 | SC 13G/A |
Recent SEC filings of DexCom
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 22, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 22, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 13, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Aug 28, 2023 | 3 | Insider Trading | |
| Aug 28, 2023 | 8-K | Current Report |
DXCM Fair Value
Loading...
Peers (Alternatives to DexCom)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 108.3B | 19.5B | 3.38% | 36.58% | 39.99 | 5.57 | 10.36% | 30.30% |
ISRG | 101.2B | 6.7B | -0.75% | 50.83% | 71.05 | 15.19 | 11.75% | -0.66% |
BSX | 77.5B | 13.4B | 6.45% | 36.39% | 85 | 5.78 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -4.29% | 12.66% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.3B | 5.7B | -8.22% | -17.24% | 30.48 | 7.49 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.5B | 937.8M | -2.12% | 37.22% | 325.65 | 10.11 | 16.30% | 250.21% |
SWAV | 7.1B | 616.6M | -12.54% | -24.86% | 29.24 | 11.56 | 69.52% | 343.68% |
GMED | 5.1B | 1.1B | -6.10% | -12.07% | 24.23 | 4.65 | 12.63% | 50.85% |
IRTC | 2.6B | 452.1M | -21.20% | -33.94% | -26.32 | 5.78 | 24.99% | 24.09% |
TNDM | 1.3B | 790.3M | -27.09% | -56.49% | -5.97 | 1.69 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -15.15% | 56.11% | -9.32 | 3.69 | 44.49% | -2.43% |
AVNS | 947.4M | 780.7M | -7.75% | -9.65% | -26.32 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 609.7M | 162.9M | -27.67% | -61.65% | -11.53 | 3.74 | 42.67% | 12.82% |
DexCom News
Returns for DXCM
Cumulative Returns on DXCM
28.7%
10-Year Cumulative Returns
20.7%
7-Year Cumulative Returns
20.2%
5-Year Cumulative Returns
-4.2%
3-Year Cumulative Returns
Risks for DXCM
What is the probability of a big loss on DXCM?
90%
Probability that DexCom stock will be more than 20% underwater in next one year
26.1%
Probability that DexCom stock will be more than 30% underwater in next one year.
23.1%
Probability that DexCom stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does DXCM drawdown profile look like?
Y-axis is the maximum loss one would have experienced if DexCom was unfortunately bought at previous high price.
Drawdowns
Financials for DexCom
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 5.8% | 3,198 | 3,023 | 2,910 | 2,793 | 2,673 | 2,572 | 2,449 | 2,319 | 2,170 | 2,027 | 1,927 | 1,821 | 1,716 | 1,601 | 1,476 | 1,351 | 1,222 | 1,128 | 1,032 | 915 | 833 |
| Gross Profit | 5.0% | 2,045 | 1,948 | 1,883 | 1,814 | 1,767 | 1,735 | 1,681 | 1,607 | 1,501 | 1,368 | 1,280 | 1,190 | 1,097 | 1,019 | 932 | 845 | 767 | 714 | 664 | 595 | 553 |
| Operating Expenses | 3.0% | 1,596 | 1,551 | 1,492 | 1,548 | 1,530 | 1,474 | 1,415 | 1,238 | 1,156 | 1,056 | 981 | 893 | 838 | 829 | 789 | 969 | 933 | 884 | 850 | 604 | 577 |
| S&GA Expenses | 4.5% | 1,124 | 1,076 | 1,000 | 936 | 900 | 838 | 807 | 747 | 707 | 657 | 618 | 574 | 539 | 541 | 516 | 499 | 479 | 452 | 433 | 414 | 393 |
| R&D Expenses | -0.5% | 465 | 467 | 484 | 518 | 536 | 544 | 517 | 487 | 445 | 396 | 360 | 320 | 299 | 288 | 274 | 252 | 236 | 214 | 200 | 191 | 184 |
| EBITDA | -100.0% | - | 599 | 565 | 434 | 385 | 366 | 376 | 440 | 416 | 393 | 377 | 374 | 330 | 266 | 213 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.20* | 0.19* | 0.16* | 0.14* | 0.14* | 0.15* | 0.19* | 0.19* | 0.19* | 0.20* | 0.21* | 0.19* | 0.17* | 0.14* | - | - | - | - | - | - |
| Interest Expenses | 6.5% | 20.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | -28.30 | -8.50 | 7.00 | 18.00 | 75.00 | 66.00 | 61.00 | 60.00 | 53.00 | 43.00 | 33.00 | 23.00 | 19.00 | 19.00 |
| Earnings Before Taxes | 20.0% | 503 | 419 | 391 | 264 | 230 | 252 | 257 | 405 | 368 | 317 | 298 | 238 | 209 | 153 | 104 | -167 | -168 | -129 | -126 | 59.00 | 12.00 |
| EBT Margin | -100.0% | - | 0.14* | 0.13* | 0.09* | 0.05* | 0.07* | 0.07* | 0.13* | 0.13* | 0.11* | 0.12* | 0.13* | 0.12* | 0.10* | 0.07* | - | - | - | - | - | - |
| Net Income | 22.2% | 358 | 293 | 341 | 244 | 230 | 258 | 217 | 634 | 618 | 586 | 550 | 231 | 205 | 148 | 101 | -171 | -170 | -129 | -127 | 43.00 | -5.40 |
| Net Income Margin | -100.0% | - | 0.10* | 0.12* | 0.09* | 0.06* | 0.09* | 0.06* | 0.24* | 0.26* | 0.25* | 0.26* | 0.13* | 0.12* | 0.09* | 0.07* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 416 | 305 | 261 | 216 | 95.00 | 53.00 | 140 | 101 | 236 | 277 | 264 | 209 | 131 | 135 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 23.7% | 6,821 | 5,516 | 5,392 | 4,899 | 5,217 | 5,057 | 4,933 | 4,776 | 4,504 | 4,390 | 4,291 | 3,833 | 3,522 | 2,448 | 2,395 | 2,186 | 2,066 | 1,974 | 1,916 | 1,114 | 1,008 |
| Current Assets | 32.8% | 5,003 | 3,767 | 3,669 | 3,399 | 3,809 | 3,747 | 3,684 | 3,656 | 3,474 | 3,445 | 3,425 | 3,237 | 3,033 | 1,996 | 1,969 | 1,816 | 1,744 | 1,691 | 1,700 | 914 | 836 |
| Cash Equivalents | 91.7% | 1,195 | 623 | 642 | 698 | 735 | 716 | 1,054 | 1,444 | 1,159 | 734 | 818 | 674 | 530 | 585 | 446 | 396 | 709 | 1,285 | 1,137 | 367 | 300 |
| Inventory | 15.1% | 421 | 366 | 307 | 311 | 340 | 342 | 357 | 351 | 319 | 290 | 235 | 201 | 165 | 142 | 120 | 120 | 118 | 101 | 71.00 | 55.00 | 46.00 |
| Net PPE | -100.0% | - | 1,076 | 1,056 | 1,003 | 943 | 857 | 802 | 742 | 676 | 590 | 515 | 462 | 384 | 346 | 321 | 301 | 253 | 221 | 183 | 170 | 157 |
| Goodwill | 0.4% | 26.00 | 26.00 | 26.00 | 25.00 | 26.00 | 27.00 | 27.00 | 24.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 18.00 | 19.00 | 19.00 | 19.00 | 18.00 | 12.00 |
| Liabilities | 43.8% | 4,720 | 3,283 | 3,260 | 3,075 | 2,962 | 2,868 | 2,891 | 2,640 | 2,506 | 2,487 | 2,464 | 2,334 | 2,168 | 1,513 | 1,512 | 1,421 | 1,378 | 1,305 | 1,253 | 552 | 525 |
| Current Liabilities | 11.0% | 2,070 | 1,865 | 1,839 | 901 | 807 | 711 | 721 | 735 | 601 | 604 | 614 | 506 | 400 | 343 | 360 | 322 | 288 | 235 | 222 | 194 | 171 |
| Shareholder's Equity | -5.9% | 2,100 | 2,233 | 2,132 | 1,825 | 2,256 | 2,189 | 2,042 | 1,912 | 1,755 | 1,645 | 1,552 | 1,499 | 1,354 | 935 | 883 | 764 | 688 | 669 | 663 | 562 | 482 |
| Retained Earnings | 21.9% | 644 | 529 | 480 | 388 | 287 | 236 | 139 | -28.00 | -98.90 | -161 | -78.20 | -557 | -629 | -675 | -695 | -788 | -834 | -823 | -798 | -619 | -665 |
| Additional Paid-In Capital | -1.6% | 2,269 | 2,306 | 2,258 | 2,072 | 2,029 | 1,997 | 2,109 | 2,322 | 2,194 | 2,162 | 1,727 | 2,154 | 2,080 | 1,707 | 1,676 | 1,652 | 1,620 | 1,591 | 1,561 | 1,182 | 1,149 |
| Accumulated Depreciation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.00 | 66.00 |
| Shares Outstanding | -0.4% | 386 | 388 | 386 | 386 | 393 | 389 | 388 | 387 | 387 | 385 | 384 | 383 | 375 | 367 | 366 | 365 | 364 | 361 | 360 | 354 | 353 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 2.3% | 771 | 754 | 670 | 643 | 597 | 486 | 443 | 509 | 409 | 502 | 476 | 447 | 394 | 305 | 315 | 205 | 167 | 144 | 123 | 131 | 110 |
| Share Based Compensation | 5.4% | 140 | 133 | 127 | 119 | 116 | 115 | 113 | 121 | 124 | 124 | 119 | 109 | 103 | 102 | 103 | 104 | 106 | 102 | 102 | 102 | 101 |
| Cashflow From Investing | -138.7% | -707 | -296 | -521 | -823 | -1,023 | -515 | -216 | 256 | 218 | -1,260 | -1,018 | -1,088 | -1,491 | -1,015 | -1,015 | -890 | -472 | 7.00 | -139 | -171 | -213 |
| Cashflow From Financing | 172.7% | 397 | -546 | -552 | -552 | 11.00 | 15.00 | 10.00 | 6.00 | - | 906 | 912 | 917 | 918 | 12.00 | 11.00 | 712 | 712 | 711 | 710 | 9.00 | 8.00 |
| Buy Backs | - | 1,115 | - | 558 | 1,115 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100 | - | - |
DXCM Income Statement
2023-06-30Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 871.3 | $ 696.2 | $ 1,612.8 | $ 1,325.0 |
| Cost of sales | 324.9 | 246.7 | 603.8 | 477.4 |
| Gross profit | 546.4 | 449.5 | 1,009.0 | 847.6 |
| Operating expenses: | ||||
| Research and development | 119.3 | 121.7 | 238.3 | 257.6 |
| Amortization of intangible assets | 1.7 | 1.9 | 3.5 | 3.9 |
| Selling, general and administrative | 297.3 | 248.9 | 591.9 | 467.8 |
| Total operating expenses | 418.3 | 372.5 | 833.7 | 729.3 |
| Operating income | 128.1 | 77.0 | 175.3 | 118.3 |
| Interest expense | (5.9) | (4.7) | (10.5) | (9.3) |
| Income from equity investments | 0.0 | 0.0 | 0.0 | 0.2 |
| Interest and other income, net | 37.1 | 3.0 | 59.0 | 2.2 |
| Income before income taxes | 159.3 | 75.3 | 223.8 | 111.4 |
| Income tax expense (benefit) | 43.4 | 24.4 | 59.3 | (36.8) |
| Net income | $ 115.9 | $ 50.9 | $ 164.5 | $ 148.2 |
| Basic net income per share (USD per share) | $ 0.30 | $ 0.13 | $ 0.43 | $ 0.38 |
| Shares used to compute basic net income per share (shares) | 386.7 | 392.5 | 386.7 | 390.7 |
| Diluted net income per share (USD per share) | $ 0.28 | $ 0.12 | $ 0.40 | $ 0.36 |
| Shares used to compute diluted net income per share (shares) | 431.5 | 421.4 | 426.6 | 429.1 |
DXCM Balance Sheet
2023-06-30Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1,194.9 | $ 642.3 |
| Short-term marketable securities | 2,441.3 | 1,813.9 |
| Accounts receivable, net | 750.6 | 713.3 |
| Inventory | 421.1 | 306.7 |
| Prepaid and other current assets | 195.0 | 192.6 |
| Total current assets | 5,002.9 | 3,668.8 |
| Property and equipment, net | 1,077.6 | 1,055.6 |
| Operating lease right-of-use assets | 76.3 | 80.0 |
| Goodwill | 25.8 | 25.7 |
| Intangibles, net | 154.2 | 173.3 |
| Deferred tax assets | 417.0 | 341.2 |
| Other assets | 66.9 | 47.1 |
| Total assets | 6,820.7 | 5,391.7 |
| Current liabilities: | ||
| Accounts payable and accrued liabilities | 1,156.5 | 901.8 |
| Accrued payroll and related expenses | 108.6 | 134.3 |
| Current portion of long-term senior convertible notes | 773.8 | 772.6 |
| Short-term operating lease liabilities | 21.8 | 20.5 |
| Deferred revenue | 9.0 | 10.1 |
| Total current liabilities | 2,069.7 | 1,839.3 |
| Long-term senior convertible notes | 2,430.6 | 1,197.7 |
| Long-term operating lease liabilities | 86.9 | 94.6 |
| Other long-term liabilities | 133.1 | 128.3 |
| Total liabilities | 4,720.3 | 3,259.9 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022 | 0.0 | 0.0 |
| Common stock, $0.001 par value, 800.0 million shares authorized; 394.6 million and 386.1 million shares issued and outstanding, respectively, at June 30, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December 31, 2022 | 0.4 | 0.4 |
| Additional paid-in capital | 2,269.0 | 2,258.1 |
| Accumulated other comprehensive loss | (29.3) | (11.6) |
| Retained earnings | 644.4 | 479.9 |
| Treasury stock, at cost; 8.5 million shares at June 30, 2023 and 6.9 million shares at December 31, 2022 | (784.1) | (595.0) |
| Total stockholders’ equity | 2,100.4 | 2,131.8 |
| Total liabilities and stockholders’ equity | $ 6,820.7 | $ 5,391.7 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.